Lynestrenol

證據等級: L5

預測適應症: 10 個

Lynestrenol: From Progestogen / Oral Contraceptive to Migraine with or without Aura

One-Sentence Summary

Lynestrenol (historically marketed as Orgametril) is a synthetic progestogen primarily used as an oral contraceptive and for hormone-related conditions, with a historical record of use in migraine prophylaxis. The TxGNN model predicts it may be relevant for Migraine with or without Aura (Susceptibility), with no registered clinical trials but 20 publications exploring the neurobiological overlap between epilepsy and migraine that forms the mechanistic backbone of this prediction. Currently, Lynestrenol is not marketed in India and detailed MOA and safety data require supplementation before this candidate can be formally evaluated.

Quick Overview

Item	Content
Original Indication	Progestogen / Oral contraceptive (no India registration found)
Predicted New Indication	Migraine with or without aura, susceptibility to
TxGNN Prediction Score	99.51%
Evidence Level	L4
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacology, Lynestrenol is a synthetic progestogen that is rapidly converted to norethisterone (a potent progestin) in the body. Its primary clinical use has been in hormonal contraception and management of menstrual disorders; notably, it was marketed as Orgametril and investigated for migraine prophylaxis as early as the 1960s (see PMID 14091721).

The top-ranked TxGNN indication — “migraine with or without aura, susceptibility to” — is closely connected to epilepsy through shared pathophysiology. Both conditions involve abnormal neuronal excitability, ion channel dysfunction (notably SCN1A variants), and neuroinflammatory cascades. The literature evidence pack predominantly captures this epilepsy-migraine mechanistic overlap, including shared genetic susceptibility (SCN1A polymorphisms, MTHFR methylation pathway) and bidirectional neuroinflammation, which likely drove the model’s high prediction score for migraine susceptibility.

The proposed pharmacological rationale is that progesterone and its metabolites may modulate neuronal excitability thresholds — possibly through neuroactive steroid metabolites (e.g., partial conversion toward allopregnanolone-like compounds that act as GABA-A positive allosteric modulators) or by stabilizing estrogen-cycle fluctuations that trigger menstrual migraine. However, this mechanistic link remains inferential, and there is a well-established safety concern: combined hormonal agents (especially those with progestogenic activity) in migraine with aura patients are associated with elevated stroke risk due to interactions with cortical spreading depression. This safety signal significantly limits the direct repurposing pathway.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

(Extracted from predicted_indications[0] — “migraine with or without aura, susceptibility to”; literature primarily addresses the epilepsy-migraine mechanistic overlap underpinning the TxGNN prediction)

PMID	Year	Type	Journal	Key Findings
33856647	2021	Review	Molecular Neurobiology	Epilepsy and migraine share ion channel mutations (SCN1A), serotonergic pathways, and neuroinflammation; discusses overlapping therapeutic strategies relevant to both conditions
23294289	2013	Genetic Study	Epilepsia	Demonstrates shared genetic susceptibility to migraine and epilepsy in the EPGP cohort, supporting the comorbidity via common genetic architecture
17460155	2007	Genetic Linkage Study	Neurology	Familial occipitotemporal lobe epilepsy co-segregating with migraine with visual aura mapped to chromosome 9q; direct genetic link between epilepsy and migraine with aura
24076350	2014	Meta-analysis	Gene	SCN1A IVS5N+5G>A polymorphism associated with epilepsy with febrile seizures susceptibility; SCN1A is also implicated in familial hemiplegic migraine pathogenesis
30267335	2018	Meta-analysis	Neurological Sciences	MTHFR C677T polymorphism as a risk factor for epilepsy; MTHFR is independently associated with migraine susceptibility, suggesting a shared metabolic/methylation pathway
34575901	2021	Review	Int J Mol Sci	Molecular targets for antiepileptogenesis; several targets (neuroinflammation, mTOR, GABAergic modulation) are also relevant in migraine prevention strategies
34209535	2021	Review	Int J Mol Sci	Bidirectional neuroinflammation in epilepsy — neuroinflammatory cascades are also central to migraine pathophysiology and represent a potential shared therapeutic target
22266888	2011	Review	Seminars in Neurology	Genetics of epilepsy as a heterogeneous neurological disorder; highlights genetic modulators of neuronal excitability applicable to migraine susceptibility research
16201993	2005	Review	Epilepsia	Developmental changes in GABAergic and glutamatergic receptor composition drive neuronal excitability; relevant to understanding how neuroactive steroids (including progestogen metabolites) may modulate seizure and migraine thresholds
28086980	2017	Review	Journal of Neuroinflammation	Neuroinflammation in post-traumatic epileptogenesis; highlights overlapping inflammatory mediators (COX-2, IL-1β, TGF-β) also implicated in central sensitization during migraine attacks

Note for reviewers: The most directly relevant Lynestrenol-migraine publication — a 1963 historical clinical observation on prophylactic migraine treatment with Lynestrenol/Orgametril (PMID 14091721) — appears in the Rank 2 indication (“migraine disorder”) evidence set. A 2026 comparative review of combined oral contraceptives in migraine (PMID 41723577) is also available there. Both are highly relevant to the overall evaluation of this candidate.

India Market Information

Lynestrenol is currently not marketed in India. No registered products were identified in the regulatory database (total registrations: 0). Regulatory approval would need to be pursued from the ground up if this candidate advances.

Safety Considerations

Critical Safety Signal: As a progestogen with partial conversion to norethisterone, Lynestrenol shares the class safety concern that combined hormonal contraceptive-class agents are contraindicated in migraine with aura due to increased ischemic stroke risk. This is a major limiting factor for the primary predicted indication.

Please refer to the package insert for complete safety information. Package insert review (TFDA/CDSCO) is currently pending and flagged as a blocking data gap (DG001).

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.51%), the evidence supporting Lynestrenol for migraine with or without aura susceptibility is limited to mechanistic and genetic overlap studies (L4), with no clinical trials and no direct clinical evidence. More critically, the predicted indication (migraine with aura) sits in direct conflict with a well-established class safety concern — progestogenic hormonal agents are generally contraindicated in this patient population due to elevated stroke risk.

To proceed, the following is needed:

MOA documentation: Retrieve full DrugBank API entry for DB12474 to confirm mechanism, receptor targets, and neuroactive metabolite profile (addresses DG002)
Regulatory safety review: Download and parse the CDSCO/TFDA package insert PDF to obtain key warnings, contraindications, and drug interaction data (addresses DG001, currently Blocking)
Safety differentiation analysis: Assess whether Lynestrenol’s specific pharmacological profile (progestogen-only, without estrogen) meaningfully separates it from the stroke-risk concern associated with combined hormonal contraceptives in migraine with aura patients
Historical evidence retrieval: Obtain full text of PMID 14091721 (1963 Orgametril migraine prophylaxis study) to characterize the clinical population, dosing, and outcomes from the historical use case
Preclinical study design: If the safety differentiation analysis is favorable, design a preclinical study targeting cortical spreading depression and trigeminovascular pathway modulation by Lynestrenol/norethisterone
India regulatory pathway assessment: Evaluate what is required for first-in-India approval given zero existing registrations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.